Share Price and Basic Stock Data
Last Updated: October 9, 2025, 12:37 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Decipher Labs Ltd, a pharmaceutical company, is currently trading at a price of ₹10.2 with a market capitalization of ₹10.3 Cr. The company’s Return on Equity (ROE) stands at 1.16%, while the Return on Capital Employed (ROCE) is at 4.67%. One concerning metric is the Operating Profit Margin (OPM) at -113.70%, indicating operational inefficiencies. The Net Profit margin also stands at -5.08%, reflecting losses. The company has a low Price-to-Book Value (P/BV) ratio of 0.46x, suggesting that the stock may be undervalued compared to its book value.
One key strength of Decipher Labs is its relatively strong promoter holding of 16.43%, indicating confidence from the company’s founders. Additionally, the company has a reasonable level of reserves at ₹12.76 Cr, providing a cushion for future investments or operational needs. However, the high level of borrowings at ₹0.24 Cr and a low Interest Coverage Ratio (ICR) of 0.00x pose significant risks to the company’s financial health. Looking ahead, improving operational efficiencies and reducing borrowings could enhance Decipher Labs’ outlook, potentially leading to better financial performance and investor confidence.
In conclusion, while Decipher Labs shows some strengths in promoter holding and reserves, the company faces challenges related to operational performance and debt management. Investors should closely monitor the company’s efforts to improve profitability and reduce borrowing levels to mitigate risks and capitalize on potential future growth opportunities.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Decipher Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 152 Cr. | 121 | 247/84.3 | 34.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,528 Cr. | 415 | 434/192 | 102 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.3 Cr. | 42.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.3 Cr. | 20.0 | 29.1/17.0 | 30.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,005.64 Cr | 1,173.77 | 51.08 | 192.71 | 0.33% | 16.15% | 14.90% | 6.18 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.62 | 12.12 | 11.06 | 9.78 | 9.51 | 7.49 | 8.29 | 10.59 | 7.44 | 5.87 | 5.80 | 3.50 | 2.92 |
| Expenses | 13.36 | 12.98 | 14.02 | 13.63 | 9.65 | 9.66 | 8.16 | 9.38 | 6.13 | 7.20 | 6.43 | 10.08 | 6.24 |
| Operating Profit | -0.74 | -0.86 | -2.96 | -3.85 | -0.14 | -2.17 | 0.13 | 1.21 | 1.31 | -1.33 | -0.63 | -6.58 | -3.32 |
| OPM % | -5.86% | -7.10% | -26.76% | -39.37% | -1.47% | -28.97% | 1.57% | 11.43% | 17.61% | -22.66% | -10.86% | -188.00% | -113.70% |
| Other Income | 6.86 | 2.66 | -4.55 | 0.15 | 0.01 | 0.14 | 0.00 | 0.27 | 0.16 | 0.12 | 0.17 | 0.87 | 0.01 |
| Interest | 0.11 | 0.12 | 0.13 | 0.07 | 0.01 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.10 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.12 |
| Profit before tax | 5.91 | 1.58 | -7.75 | -3.89 | -0.25 | -2.14 | 0.01 | 1.16 | 1.36 | -1.33 | -0.58 | -5.84 | -3.43 |
| Tax % | 0.00% | 24.05% | 0.13% | 9.77% | 280.00% | -9.35% | 0.00% | -3.45% | 30.15% | 0.00% | 1.72% | -29.62% | 0.00% |
| Net Profit | 5.91 | 1.19 | -7.75 | -4.27 | -0.95 | -1.94 | 0.01 | 1.20 | 0.95 | -1.33 | -0.59 | -4.11 | -3.43 |
| EPS in Rs | 5.85 | 1.18 | -7.67 | -4.23 | -0.94 | -1.92 | 0.01 | 1.19 | 0.94 | -1.32 | -0.58 | -4.07 | -3.40 |
Last Updated: August 19, 2025, 8:20 pm
Below is a detailed analysis of the quarterly data for Decipher Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2.92 Cr.. The value appears to be declining and may need further review. It has decreased from 3.50 Cr. (Mar 2025) to 2.92 Cr., marking a decrease of 0.58 Cr..
- For Expenses, as of Jun 2025, the value is 6.24 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.08 Cr. (Mar 2025) to 6.24 Cr., marking a decrease of 3.84 Cr..
- For Operating Profit, as of Jun 2025, the value is -3.32 Cr.. The value appears strong and on an upward trend. It has increased from -6.58 Cr. (Mar 2025) to -3.32 Cr., marking an increase of 3.26 Cr..
- For OPM %, as of Jun 2025, the value is -113.70%. The value appears strong and on an upward trend. It has increased from -188.00% (Mar 2025) to -113.70%, marking an increase of 74.30%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.87 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.86 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.12 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.13 Cr. (Mar 2025) to 0.12 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is -3.43 Cr.. The value appears strong and on an upward trend. It has increased from -5.84 Cr. (Mar 2025) to -3.43 Cr., marking an increase of 2.41 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -29.62% (Mar 2025) to 0.00%, marking an increase of 29.62%.
- For Net Profit, as of Jun 2025, the value is -3.43 Cr.. The value appears strong and on an upward trend. It has increased from -4.11 Cr. (Mar 2025) to -3.43 Cr., marking an increase of 0.68 Cr..
- For EPS in Rs, as of Jun 2025, the value is -3.40. The value appears strong and on an upward trend. It has increased from -4.07 (Mar 2025) to -3.40, marking an increase of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 1:57 pm
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 22.61 |
| Expenses | 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 29.84 |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | -7.23 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | -31.98% |
| Other Income | 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | 1.32 |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.48 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | -6.39 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | -20.50% |
| Net Profit | 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | -5.08 |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | -5.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 127.78% | 168.29% | 27.27% | 712.86% | -123.55% | 37.31% | -202.38% |
| Change in YoY Net Profit Growth (%) | 0.00% | 40.51% | -141.02% | 685.58% | -836.41% | 160.86% | -239.69% |
Decipher Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -30% |
| TTM: | -47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -4400% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -15% |
| 3 Years: | -39% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | -4% |
| Last Year: | -23% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: October 10, 2025, 3:52 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 11.76 | 12.76 |
| Borrowings | 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | 0.24 |
| Other Liabilities | 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 11.77 | 2.66 |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 |
| Fixed Assets | 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 2.91 | 2.54 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 3.39 | 0.26 |
| Other Assets | 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 27.33 | 22.96 |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 |
Below is a detailed analysis of the balance sheet data for Decipher Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.10 Cr..
- For Reserves, as of Mar 2025, the value is 12.76 Cr.. The value appears strong and on an upward trend. It has increased from 11.76 Cr. (Mar 2024) to 12.76 Cr., marking an increase of 1.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.24 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2024) to 0.24 Cr., marking an increase of 0.24 Cr..
- For Other Liabilities, as of Mar 2025, the value is 2.66 Cr.. The value appears to be improving (decreasing). It has decreased from 11.77 Cr. (Mar 2024) to 2.66 Cr., marking a decrease of 9.11 Cr..
- For Total Liabilities, as of Mar 2025, the value is 25.76 Cr.. The value appears to be improving (decreasing). It has decreased from 33.63 Cr. (Mar 2024) to 25.76 Cr., marking a decrease of 7.87 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2.54 Cr.. The value appears to be declining and may need further review. It has decreased from 2.91 Cr. (Mar 2024) to 2.54 Cr., marking a decrease of 0.37 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.26 Cr.. The value appears to be declining and may need further review. It has decreased from 3.39 Cr. (Mar 2024) to 0.26 Cr., marking a decrease of 3.13 Cr..
- For Other Assets, as of Mar 2025, the value is 22.96 Cr.. The value appears to be declining and may need further review. It has decreased from 27.33 Cr. (Mar 2024) to 22.96 Cr., marking a decrease of 4.37 Cr..
- For Total Assets, as of Mar 2025, the value is 25.76 Cr.. The value appears to be declining and may need further review. It has decreased from 33.63 Cr. (Mar 2024) to 25.76 Cr., marking a decrease of 7.87 Cr..
Notably, the Reserves (12.76 Cr.) exceed the Borrowings (0.24 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.06 | 0.25 | -8.76 | -12.91 | -4.29 | -5.12 | -0.68 | -7.47 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Inventory Days | 91.25 | 19.70 | 0.00 | |||||
| Days Payable | 511.00 | 192.66 | ||||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Working Capital Days | 751.47 | 99.63 | -2.13 | -11.50 | 65.43 | 61.67 | 36.52 | 247.48 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% | -4.67% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -5.03 | -1.66 | -2.66 | 11.27 | 1.39 |
| Diluted EPS (Rs.) | -5.03 | -1.66 | -2.66 | 11.27 | 1.39 |
| Cash EPS (Rs.) | -4.56 | -1.21 | -2.23 | 12.13 | 2.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 |
| Revenue From Operations / Share (Rs.) | 22.39 | 35.52 | 45.12 | 64.67 | 55.01 |
| PBDIT / Share (Rs.) | -5.85 | -0.53 | -1.05 | 13.56 | 4.05 |
| PBIT / Share (Rs.) | -6.32 | -0.98 | -1.48 | 12.71 | 3.24 |
| PBT / Share (Rs.) | -6.32 | -1.20 | -4.12 | 12.23 | 2.12 |
| Net Profit / Share (Rs.) | -5.03 | -1.66 | -2.65 | 11.27 | 1.39 |
| NP After MI And SOA / Share (Rs.) | -5.03 | -1.66 | -2.65 | 11.27 | 1.39 |
| PBDIT Margin (%) | -26.13 | -1.50 | -2.33 | 20.97 | 7.37 |
| PBIT Margin (%) | -28.24 | -2.76 | -3.27 | 19.64 | 5.89 |
| PBT Margin (%) | -28.24 | -3.37 | -9.12 | 18.91 | 3.85 |
| Net Profit Margin (%) | -22.46 | -4.67 | -5.88 | 17.42 | 2.52 |
| NP After MI And SOA Margin (%) | -22.46 | -4.67 | -5.88 | 17.42 | 2.52 |
| Return on Networth / Equity (%) | -22.22 | -7.66 | -11.55 | 47.10 | 10.24 |
| Return on Capital Employeed (%) | -27.94 | -4.54 | -6.17 | 41.60 | 15.30 |
| Return On Assets (%) | -19.71 | -4.98 | -9.52 | 27.13 | 3.62 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.04 | 0.27 | 0.49 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.04 | 0.42 | 0.63 |
| Asset Turnover Ratio (%) | 0.76 | 1.16 | 1.30 | 0.03 | 0.04 |
| Current Ratio (X) | 7.24 | 2.10 | 5.01 | 3.44 | 1.30 |
| Quick Ratio (X) | 7.24 | 2.10 | 5.01 | 3.44 | 1.30 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.82 |
| Interest Coverage Ratio (X) | 0.00 | -2.49 | -2.49 | 28.74 | 3.61 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | -6.70 | -0.03 | 24.89 | 2.24 |
| Enterprise Value (Cr.) | 8.05 | 5.60 | 7.86 | 48.39 | 35.56 |
| EV / Net Operating Revenue (X) | 0.35 | 0.15 | 0.17 | 0.74 | 0.64 |
| EV / EBITDA (X) | -1.36 | -10.36 | -7.39 | 3.53 | 8.68 |
| MarketCap / Net Operating Revenue (X) | 0.46 | 0.41 | 0.31 | 0.81 | 0.60 |
| Price / BV (X) | 0.46 | 0.68 | 0.61 | 2.21 | 2.47 |
| Price / Net Operating Revenue (X) | 0.46 | 0.41 | 0.31 | 0.81 | 0.60 |
| EarningsYield | -0.47 | -0.11 | -0.18 | 0.21 | 0.04 |
After reviewing the key financial ratios for Decipher Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 5. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For Diluted EPS (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 5. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.56. This value is below the healthy minimum of 3. It has decreased from -1.21 (Mar 24) to -4.56, marking a decrease of 3.35.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.63. It has increased from 21.64 (Mar 24) to 22.63, marking an increase of 0.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.63. It has increased from 21.64 (Mar 24) to 22.63, marking an increase of 0.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 22.39. It has decreased from 35.52 (Mar 24) to 22.39, marking a decrease of 13.13.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -5.85. This value is below the healthy minimum of 2. It has decreased from -0.53 (Mar 24) to -5.85, marking a decrease of 5.32.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.32. This value is below the healthy minimum of 0. It has decreased from -0.98 (Mar 24) to -6.32, marking a decrease of 5.34.
- For PBT / Share (Rs.), as of Mar 25, the value is -6.32. This value is below the healthy minimum of 0. It has decreased from -1.20 (Mar 24) to -6.32, marking a decrease of 5.12.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 2. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 2. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For PBDIT Margin (%), as of Mar 25, the value is -26.13. This value is below the healthy minimum of 10. It has decreased from -1.50 (Mar 24) to -26.13, marking a decrease of 24.63.
- For PBIT Margin (%), as of Mar 25, the value is -28.24. This value is below the healthy minimum of 10. It has decreased from -2.76 (Mar 24) to -28.24, marking a decrease of 25.48.
- For PBT Margin (%), as of Mar 25, the value is -28.24. This value is below the healthy minimum of 10. It has decreased from -3.37 (Mar 24) to -28.24, marking a decrease of 24.87.
- For Net Profit Margin (%), as of Mar 25, the value is -22.46. This value is below the healthy minimum of 5. It has decreased from -4.67 (Mar 24) to -22.46, marking a decrease of 17.79.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -22.46. This value is below the healthy minimum of 8. It has decreased from -4.67 (Mar 24) to -22.46, marking a decrease of 17.79.
- For Return on Networth / Equity (%), as of Mar 25, the value is -22.22. This value is below the healthy minimum of 15. It has decreased from -7.66 (Mar 24) to -22.22, marking a decrease of 14.56.
- For Return on Capital Employeed (%), as of Mar 25, the value is -27.94. This value is below the healthy minimum of 10. It has decreased from -4.54 (Mar 24) to -27.94, marking a decrease of 23.40.
- For Return On Assets (%), as of Mar 25, the value is -19.71. This value is below the healthy minimum of 5. It has decreased from -4.98 (Mar 24) to -19.71, marking a decrease of 14.73.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 1.16 (Mar 24) to 0.76, marking a decrease of 0.40.
- For Current Ratio (X), as of Mar 25, the value is 7.24. This value exceeds the healthy maximum of 3. It has increased from 2.10 (Mar 24) to 7.24, marking an increase of 5.14.
- For Quick Ratio (X), as of Mar 25, the value is 7.24. This value exceeds the healthy maximum of 2. It has increased from 2.10 (Mar 24) to 7.24, marking an increase of 5.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -2.49 (Mar 24) to 0.00, marking an increase of 2.49.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -6.70 (Mar 24) to 0.00, marking an increase of 6.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8.05. It has increased from 5.60 (Mar 24) to 8.05, marking an increase of 2.45.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 1. It has increased from 0.15 (Mar 24) to 0.35, marking an increase of 0.20.
- For EV / EBITDA (X), as of Mar 25, the value is -1.36. This value is below the healthy minimum of 5. It has increased from -10.36 (Mar 24) to -1.36, marking an increase of 9.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.46, marking an increase of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.68 (Mar 24) to 0.46, marking a decrease of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.46, marking an increase of 0.05.
- For EarningsYield, as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.11 (Mar 24) to -0.47, marking a decrease of 0.36.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Decipher Labs Ltd:
- Net Profit Margin: -22.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -27.94% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -22.22% (Industry Average ROE: 14.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.24
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 51.08)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -22.46%
About the Company - Qualitative Analysis
Decipher Labs Ltd. is a Public Limited Listed company incorporated on 17/09/1986 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24230TG1986PLC006781 and registration number is 006781. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 0.85 Cr. and Equity Capital is Rs. 10.10 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Hyderabad Telangana 500081 | cs@decipherlabs.in www.decipherlabs.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sushant Mohan Lal | Executive Director |
| Mr. Janaki Ram Ajjarapu | Non Executive Director |
| Mr. G Venkateswara Rao | Independent Director |
| Mrs. Lakshmi Vijaya Nimmala | Independent Director |
| Mrs. Gayathri Raghuram | Independent Director |
FAQ
What is the intrinsic value of Decipher Labs Ltd?
Decipher Labs Ltd's intrinsic value (as of 10 October 2025) is 3.21 which is 67.90% lower the current market price of 10.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹10.1 Cr. market cap, FY2025-2026 high/low of 17.3/9.61, reserves of ₹12.76 Cr, and liabilities of 25.76 Cr.
What is the Market Cap of Decipher Labs Ltd?
The Market Cap of Decipher Labs Ltd is 10.1 Cr..
What is the current Stock Price of Decipher Labs Ltd as on 10 October 2025?
The current stock price of Decipher Labs Ltd as on 10 October 2025 is 10.0.
What is the High / Low of Decipher Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Decipher Labs Ltd stocks is 17.3/9.61.
What is the Stock P/E of Decipher Labs Ltd?
The Stock P/E of Decipher Labs Ltd is .
What is the Book Value of Decipher Labs Ltd?
The Book Value of Decipher Labs Ltd is 22.6.
What is the Dividend Yield of Decipher Labs Ltd?
The Dividend Yield of Decipher Labs Ltd is 0.00 %.
What is the ROCE of Decipher Labs Ltd?
The ROCE of Decipher Labs Ltd is 4.67 %.
What is the ROE of Decipher Labs Ltd?
The ROE of Decipher Labs Ltd is 1.16 %.
What is the Face Value of Decipher Labs Ltd?
The Face Value of Decipher Labs Ltd is 10.0.